Outlook Therapeutics, Inc. OTLKW 深 滬

Outlook Therapeutics’ Resubmitted ONS-5010 BLA Accepted by FDA

Outlook Therapeutics ( ($OTLK) ) has provided an update. On June 16, 2026, Outl...

06-16 21:49

Outlook gains as wet AMD therapy reconsidered for FDA review

Outlook Therapeutics (OTLK) traded higher in the premarket on Tuesday after the U.S. Food and Drug Administration agreed to reconsider its marketing application for ONS-5010, a treatment targeting the...

06-16 21:23

Intel To Rally Around 26%? Here Are 10 Top Analyst Forecasts For Thursday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. BTIG raised the price target for Chefs’ Warehouse Inc (NASDAQ:CHEF) from $82 to $100. BTIG analyst Peter Saleh...

06-11 19:49

Ascendiant Capital Maintains Buy on Outlook Therapeutics, Raises Price Target to $10

Ascendiant Capital analyst Edward Woo maintains Outlook Therapeutics (NASDAQ:OTLK) with a Buy and raises the price target from $6 to $10.

06-11 17:46

Outlook Therapeutics Resubmits FDA Application for ONS-5010

Outlook Therapeutics ( ($OTLK) ) has provided an announcement. On June 1, 2026,...

06-01 22:40

Outlook Therapeutics Announces Insider-Backed Direct Stock Offering

Outlook Therapeutics ( ($OTLK) ) has issued an announcement. On May 28, 2026, O...

05-29 06:48

Outlook Therapeutics prices $5M registered direct offering

Outlook Therapeutics (Nasdaq: OTLK) on Thursday said it priced a registered direct offering of about 8.54 million shares of common stock at $0.5855 per share to GMS Ventures and Investments, its large...

05-29 04:11

Outlook Therapeutics Announces Pricing of $5.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Outlook Therapeutics, Inc. has entered into a definitive agreement to sell 8,539,709 shares of its common stock at $0.5855 per share, raising approximately $5.0 million. Proceeds will be used for working capital and general corporate purposes. The company also amended warrants previously issued to GMS Ventures and Investments, reducing the exercise price to $0.5855 per share. Outlook Therapeutics focuses on developing and commercializing ONS-5010...

05-28 20:00

Outlook Shares Jump Following FDA Appeal Decision For LYTENAVA

Outlook Therapeutics Inc. shares are trading higher Tuesday after the FDA granted its appeal in the ONS-5010 dispute resolution process.

05-26 21:16

Outlook Therapeutics Wins Appeal Following Formal Dispute Resolution Process for ONS-5010/LYTENAVA™ (bevacizumab-vikg)

05-26 11:00